• Explore /
  • Poster
  • / Patients with <em>EGFR</em> mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.

Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.

Abstract Poster

Authors

Xiuning Le

Xiuning Le

Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Xiuning Le , Anna Eisert , Te-Chun Hsia , Nirmal Vivek Raut , Azura Ahmad , Oscar Siu Hong Chan , Charlotte De Bondt , David Farrugia , Patrizia Froesch , Maria González-Cao , Lizza Hendriks , Maximilian J. Hochmair , Julien Mazieres , Hazel O’Sullivan , Jens Samol , Anthonie J. van der Wekken , Tsung-Ying Yang , Kirti Joshi , Soetkin Vlassak , Gee-Chen Chang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9070)

DOI

10.1200/JCO.2023.41.16_suppl.9070

Abstract #

9070

Poster Bd #

58

Abstract Disclosures

Similar Posters

First Author: Rahul Shenolikar

First Author: Satoru Miura

First Author: Kiyoaki Uryu

First Author: Daniel Shao-Weng Tan